ViGenCell Company Description

ViGenCell Inc. provides immune cell therapy in South Korea.

It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications.

The company was founded in 2013 and is based in Seoul, South Korea.

ViGenCell Inc.

Country	South Korea
Founded	2013
Industry	Biological Products, Except Diagnostic Substances
Employees	64
CEO	Kim Tai Gyu

Contact Details

Address: The Reason Valley Knowledge Industry Complex Seoul, 08513 South Korea
Phone	82 2 785 0201
Website	vigencell.com

Stock Details

Ticker Symbol	308080
Exchange	KOSDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Kim Tai Gyu	Chief Executive Officer